Levels of pro-inflammatory biomarkers among HIV patients on highly active antiretroviral therapy (HAART) and HAART naive patients

Osei Kwame Wiredu; Fred Jonathan Edzeamey; Margaret Twimasiwah Frempong; Delphine Gborgblorvor Delphine; Bernard Berko Sampong; Maxwell Awuah; Albert Dompreh

doi:10.30574/gscbps.2018.4.2.0056

Authors

Osei Kwame Wiredu Department of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Ghana.
Fred Jonathan Edzeamey Laboratory Department, Ashanti-Bekwai Municipal Hospital, Ghana.
Margaret Twimasiwah Frempong Department of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Ghana.
Delphine Gborgblorvor Delphine Department of Out-Patients’, Ashanti-Bekwai Municipal Hospital, Ghana.
Bernard Berko Sampong Laboratory Department, Ashanti-Bekwai Municipal Hospital, Ghana.
Maxwell Awuah Department of Medical Laboratory Technology, School of Allied Health Sciences, University of Cape Coast, Ghana.
Albert Dompreh Serology Department, Komfo Anokye Teaching Hospital, Kumasi, Ghana.

DOI:

https://doi.org/10.30574/gscbps.2018.4.2.0056

Keywords:

Pro-inflammatory, HAART naïve, HIV, Biomarkers

Abstract

Inflammation is the immune response of the body to infection and injury. Inflammation aims at eliminating the pathogen or causative agent, removing necrotic cells and tissues and initiating repair process. IL-6. TNF-α and CRP are biomarkers of inflammation. This study sought to determine the pro-inflammatory markers among HIV patients on HAART and HAART naïve patients. This was a hospital-based, case control study conducted among 150 participants. HIV patients’ on HAART (n = 50) and HAART naïve HIV (n = 50) patients and the control group (n = 50) was HIV Seronegative individuals. Venous blood was drawn from each of the participant. Serial dilutions of standards of TNF-α, IL-6 and CRP were made and mixed with 10 μL of patients’ blood. Absorbance was read at 450nm within 15min with Mindray MR-96A reader. Among the study population, IL-6 levels was higher in HAART naïve HIV patients 17.66(13.00 - 24.10) ng/L, and these same group also recorded the highest CRP and TNF-α levels of 1453(328.8 – 2510) µg/L and 318.3(123.0 - 497.9) ng/L respectively. The present study revealed elevated levels of pro-inflammatory cytokines (IL-6, CRP and TNF-α) in seropositive HIV groups compared to seronegative group.

Metrics

Metrics Loading ...

References

Pasquereau S, Kumar A and Herbein G. (2017). Targeting TNF and TNF receptor pathway in HIV-1 infection: from immune activation to viral reservoirs. Viruses 9, 64.

Hagaa T, Eﬁrd JT, Tugizov S and Palefsky JM. (2016). Increased TNF-alpha and sTNFR2 levels are associated with high-grade anal squamous intraepithelial lesions in HIV-positive patients with low CD4 level. Papillomavirus Research, 3, 1-6.

Kumar A, Abbas W and Herbein G. (2013). TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy? Mediators of Inflammation, 1-14.

Borges AH, O’Connor JL, Phillips AN, Rönsholt FF, Pett S, Vjecha MJ, French MA and Lundgren JD. (2015). Factors associated with plasma IL-6 Levels during HIV infection. The Journal of Infectious Diseases, 212, 585–95.

Shive CL, Biancotto A, Funderburg NT, Pilch Cooper HA, Valdez H, Margolis L, Sieg SF, McComsey GA, Rodriguez B and Lederman MM. (2012). HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. Journal of Acquired Immune Deficiency Syndromes, 61(2), 145–152.

Salter ML, Lau B, Mehta SH, Go VF, Leng S and Kirk GD. (2013). Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high-risk for HCV and HIV infections. Journal of Acquired Immune Deficiency Syndromes, 64(5), 1-14.

Wiredu OK, Edzeamey FJ, Dompreh A, Awuah M, Ako AK, Sampong BB, Ahmed S and Yeboah EK. (2018). Lymphocyte subset (CD3, CD4 and CD8 Cells) and their ratios in HIV patients on highly active antiretroviral therapy (HAART) and HAART naïve patients. International Journal of Microbiology and Advanced Immunology, 06(2), 92-95.

Ishihara K and Hirano T. (2002). IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Review, 13, 357-68.

Rifai N, Joubran R, Yu H, Asmi M and Jouma M. (1999). Inflammatory markers in men with angiographically documented coronary heart disease. Clinical Chemistry, 45, 1967-73.

Edzeamey FJ and Ako AK (2018). HIV Infection and Therapeutic Interventions: Review on HIV Infection Biology, Highly Active Antiretroviral Therapy (HAARTs), Hepatotoxicity, Nephrotoxicity and Dyslipidemia. International Journal of Research and Reports in Hematology, 1(1): 1-11

Ownby RL, Kumar AM, Fernandez JB, Moleon-Borodowsky I, Gonzalez L, Eisdorfer S, Waldrop-Valverde D and Kumar M. (2009). Tumor Necrosis Factor-alpha Levels in HIV-1 Seropositive Injecting Drug Users. Journal of Neuroimmune Pharmacology, 4(3), 350–358.

Lau DC, Dhillon B, Yan H, Szmitko PE and Verma S. (2005). Adipokines: molecular links between obesity and atheroslcerosis. American Journal of Physiology-Heart and Circulatory, 288, H2031-41.

Pepys MB, and Hirschfield GM. (2003). C-reactive protein: a critical update. Journal of Clinical Investigation, 111, 1805-12.

Clyne B, and Olshaker JS. (1999). The C-reactive protein. Journal of Emergency Medicine, 17, 1019-25.

Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B and Gange SJ. (2006). C-reactive protein is a marker for human immunodeficiency virus disease progression. Archives of Internal Medicine, 166, 64-70.

Triant VA, Meigs JB and Grinspoon SK. (2009). Association of C - reactive protein and HIV infection with acute myocardial infarction. Journal of Acquired Immune Deficiency Syndromes, 51(3), 268–273.

Eylar EH, Lefranc CE, Yamamura Y, Ineabely Báez I, Colón-Martinez SL, Rodriguez N and Breithaupt TB. (2001). HIV infection and aging: enhanced Interferon- and Tumor Necrosis Factor-alpha production by the CD8+ CD28- T subset. BMC Immunology 2, 10.

Poli G, Kinter AL and Fauci AS. (1994). Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America, 91, 108-12.

Gauldie J, Richards C, Northemann W, Fey G and Baumann H. (1989). IFNβ2/BSF2/IL‐6 is the monocyte‐derived HSF that regulates receptor‐specific acute phase gene regulation in hepatocytes. Annals of the New York Academy of Sciences, 557(1), 46-59.

Black S, Kushner I and Samols D. (2004). C-reactive protein. Journal of Biological Chemistry, 279, 48487-90.

Ridker PM. (2003). Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 107, 363-9.

Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B and Gange SJ. (2006). C - reactive protein is a Marker for Human Immunodeficiency Virus Disease Progression. Archives of Internal Medicine, 166, 64-70.